Global Sports Nutrition Market Topped $27.2B in 2007

September 17, 2008

WELLESLEY, Mass.—The global market for sports nutrition was worth $27.2 billion in 2007, according to a new report from market research firm BCC Research. The organization further estimated sales will top $31.2 billion in 2008 and reach $91.8 by 2013, a compound annual growth rate (CAGR) of 24.1 percent.

BCC’s report, Sports Nutrition and High Energy Supplements: The Global Market, breaks down the market into sports beverages, sports food and sports supplements, with beverages taking the largest market share and growing at the fastest rate. Revenues for sports beverages were $24.9 billion in 2007, and are expected to have a CAGR of 25.6 percent through 2013, resulting in an $87.0 billion market. The sports food segment was worth $1.2 billion in 2007 and will reach an estimated $1.5 billion in 2008. This should increase to $2.5 billion in 2013, for a CAGR of 10.0 percent. The sports supplements segment was worth $1.1 billion in 2007 and will reach an estimated $1.9 billion in 2008. This should reach $2.3 billion in 2013, a CAGR of 4.0 percent.

According to BCC, the United States is the largest consumer market for sports nutrition products, followed by Western Europe and Japan. Key market drivers include taste, price, variety and brand trust. Now that the demand for sports nutrition products is coming from mainstream consumers, convenience and taste are seen as the biggest growth drivers.¹

¹Natural Products Insider

read more | digg story

Bookmark and Share

Advertisements

Global Market for DNA Sequencing Worth $1.7 Billion by 2013

August 11, 2008

Wellesley, Mass—According to a new technical market research report, DNA SEQUENCING: EMERGING TECHNOLOGIES AND APPLICATIONS (BIO045B) from BCC Research, the global market for DNA sequencing technology was worth $794.0 million in 2007 and an estimated $862.5 million in 2008. This should increase to $1.7 billion by 2013, a compound annual growth rate (CAGR) of 14.7%.

The market is broken down into the segments of research/drug discovery and development, commercial applications and emerging applications. Research/drug discovery and development has the largest share of the market, generating $600.4 million in 2007. This is expected to increase to $640.6 million in 2008 and over $1.0 billion in 2013, for a CAGR of 9.7%.

Commercial applications have the next largest share of the market, worth $193.6 million in 2007 and an estimated $218.8 million in 2008. This should increase at a CAGR of 14.3% to reach $426.1 million in 2013.

Emerging applications have the smallest but fastest growing share of the market. This sector is expected to generate $3.1 million by the end of 2008 and $272.5 million in 2013, for a CAGR of 144.8%.

DNA sequencing allows us to catalogue the variations within the human genome sequence that make us phenotypically different, and that cause resistance and susceptibility to disease. The rapidly evolving sequencing technologies provide unprecedented analytical tools that allow us to identify this sequence variation, in humans as well as in other species.

Technology and market forces are working a fundamental shift in the DNA sequencing industry away from stagnant/declining growth towards high growth. This growth inflection signals the arrival of DNA sequencing as a premier genetic analysis tool: useful for existing applications such as de novo whole genome sequencing and entirely new applications like epigenetic tag sequencing.

FIGURE
GLOBAL VALUE OF DNA SEQUENCING, BY END USE APPLICATION,
2006-2013
($ millions)

read more | digg story

Bookmark and Share


Stem Cell Development Continuing at a Blistering Speed

August 1, 2008

US MARKET FOR STEM CELL TECHNOLOGIES SLATED FOR HIGH GROWTH THROUGH 2012

Wellesley, Mass—According to a new technical market research report, STEM CELL TECHNOLOGY: CURRENT APPLICATIONS AND FUTURE DIRECTIONS (BIO035C) from BCC Research, the domestic market for stem cell technology is expected to increase from $112.0 million in 2007 to $423.1 million in 2012, a compound annual growth rate (CAGR) of 30.5%

The market is divided into cellular therapeutics and therapeutic banking categories. Stem cells in therapeutic banking have the larger share of the market, worth $65.9 million in 2007 and expected to increase to $155.7 million in 2012, for a CAGR of 18.8%.

Cellular therapeutics should be the faster growing segment. Cellular therapeutics generated $46.1 million in 2007 and is expected to generate $267.4 million in 2012, a CAGR of 42.1%.

The advent of stem cell technology has reignited the regenerative medicine market with hopes of powerful new therapeutics geared towards addressing unmet healthcare needs such as cardiovascular disease, neurological diseases, metabolic diseases, organ failure, a wide range of injuries, and even age related degeneration.

Although stem cell based therapeutics hold great promise, the delivery of actual readily available treatments is still projected to be at least five if not 10 or more years away. People looking to capitalize on the potential future therapeutic applications of stem cells have been preserving their stem cells, and stem cell banking has become a slow but growing market.

Stem cell research and development will continue to play a significant role in the present and future commercialization of stem cell based products and services and may develop into a substantial parallel market to stem cell based therapeutics as these tools mature, and potentially move into adjacent life science markets such as pharmaceutical testing and drug discovery.

Contact: Jason W. Prokowiew

Tel: 978-870-3345

Email: jason.prokowiew@bccresearch.com

read more | digg story

Bookmark and Share


Global Market for Cancer Therapies Slated for High Growth Through 2013

July 16, 2008

WELLESLEY, Mass., July 16, 2008–According to a new technical market research report, CANCER THERAPIES: TECHNOLOGIES AND GLOBAL MARKETS (HLC027B) from BCC Research, the global market for cancer therapies will be worth $47.3 billion in 2008. This should increase to over $110.6 billion by 2013, a compound annual growth rate (CAGR) of 12.6%.

The four main types of cancer therapy are chemotherapy, hormone therapy, target therapy and immunotherapy. Of these, the target therapy segment has the largest share of the market. Worth an estimated $22.9 billion in 2008, this segment should reach $69.1 billion in 2013, for a CAGR of 24.7%. Target therapy comprised approximately 45.0% of the overall market in 2007. This figure is expected to increase to 48.0% by the end of 2008 and 62.5% in 2013.

Chemotherapy has the second largest share of the market, worth $13.1 billion in 2007. This segment is expected to reach $14.3 billion in 2008 and $24.3 billion in 2013, for a CAGR of 11.2%.

The breast cancer therapy segment dominated the overall market in 2007 with 26.0% of the market share and $10.6 billion in revenue. This segment is forecast to reach $12.4 billion in 2008 and $26.5 billion in 2013, for a CAGR of 16.4%.

Although significant improvements in the diagnosis and development of various compounds to treat cancer have been made, cancer remains a major healthcare challenge worldwide. More than 11 million people are diagnosed with cancer every year, and the cancer therapy market is the second largest pharmaceutical market in terms of revenue after the cardiovascular drug market.

Data and analysis extracted from this press release must be accompanied by a statement identifying

BCC Research (www.bccresearch.com), 40 Washington Street, Suite 110, Wellesley, MA;
Telephone: 866-285-7215, editor@bccresearch.com as the source and publisher.

Additional Releases: http://www.bccresearch.com/press.htm

BCC Research is a leading publisher of market research reports and technical publications. Forthcoming report information can be found on our Web site at http://www.bccresearch.com

Contact:
Jason W. Prokowiew
Tel: 978-870-3345
Email: jason.prokowiew@bccresearch.com

read more | digg story

Bookmark and Share


Patients and doctors finding benefits in probiotics

July 9, 2008

PEORIA — Probiotics have long resided in the human gut. Only recently has the word moved to the tip of the tongue of many central Illinoisans. “People read about it and are interested,” said Dr. Antoine Dawalibi, who practices family medicine at Methodist Medical Group at Peartree. ¹

¹Ori, Ryan Peoria Illinois Journal

read more | digg story

Bookmark and Share


Robotics Give Doctors A Helping Hand

June 19, 2008

Advances in robotics technology are completely transforming today’s hospital operating rooms. With robot control and assistance, surgery for any kind of injury or ailment is faster, more accurate, and less invasive than ever before.¹

¹Roger Allan, Electronic Design

read more | digg story

Bookmark and Share


Pondering Probiotics

June 12, 2008

What if, rather than conferring a benefit to the digestive tract, probiotics worked by slowing the pace of bacterial die-off in organs near the gut, or even in other areas of the gut itself?¹

¹Amy Proal; Bacteriality–Understanding Chronic Disease

read more | digg story

Bookmark and Share